Iradimed Corporation (NASDAQ:IRMD) Shares Sold by Trexquant Investment LP

Trexquant Investment LP decreased its holdings in shares of Iradimed Corporation (NASDAQ:IRMDFree Report) by 58.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,869 shares of the medical equipment provider’s stock after selling 6,827 shares during the quarter. Trexquant Investment LP’s holdings in Iradimed were worth $231,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Iradimed by 2.7% during the third quarter. Vanguard Group Inc. now owns 412,151 shares of the medical equipment provider’s stock worth $18,287,000 after purchasing an additional 10,932 shares during the last quarter. RK Capital Management LLC boosted its holdings in Iradimed by 4.4% in the third quarter. RK Capital Management LLC now owns 300,800 shares of the medical equipment provider’s stock valued at $13,346,000 after acquiring an additional 12,700 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Iradimed by 2.3% in the fourth quarter. Russell Investments Group Ltd. now owns 211,288 shares of the medical equipment provider’s stock valued at $10,030,000 after acquiring an additional 4,715 shares during the last quarter. Resource Consulting Group Inc. acquired a new position in Iradimed in the fourth quarter valued at $4,889,000. Finally, Bridge City Capital LLC acquired a new position in Iradimed in the third quarter valued at $1,250,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Iradimed Stock Performance

Shares of NASDAQ IRMD opened at $42.76 on Wednesday. Iradimed Corporation has a 1 year low of $36.12 and a 1 year high of $51.04. The firm has a market cap of $541.34 million, a price-to-earnings ratio of 30.33 and a beta of 0.80. The stock’s 50-day simple moving average is $42.41 and its 200-day simple moving average is $43.51.

Iradimed (NASDAQ:IRMDGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. Iradimed had a return on equity of 24.63% and a net margin of 26.48%. The business had revenue of $17.60 million for the quarter, compared to analyst estimates of $17.26 million. As a group, research analysts predict that Iradimed Corporation will post 1.41 EPS for the current year.

Iradimed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 30th. Investors of record on Monday, May 20th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 1.40%. The ex-dividend date of this dividend was Friday, May 17th. Iradimed’s dividend payout ratio is currently 42.55%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Roth Capital reiterated a “buy” rating on shares of Iradimed in a report on Monday, April 22nd. Singular Research reiterated a “buy” rating on shares of Iradimed in a report on Monday, April 1st. Finally, Roth Mkm reiterated a “buy” rating and issued a $65.00 target price on shares of Iradimed in a report on Monday, April 22nd.

Read Our Latest Research Report on IRMD

About Iradimed

(Free Report)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.

Read More

Institutional Ownership by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.